Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Medecine Sciences : M/S|July 13, 2010
[Could idiosyncratic thinking fit with >?]Céline Narjoz, Philippe Beaune, Isabelle de Waziers
Cancer Chemotherapy and Pharmacology|September 13, 2021
Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive resultsClotilde Gaible, Céline Narjoz, Marie-Anne Loriot, et al.
Pharmacogenomics|October 29, 2020
Identification of rare defective allelic variants in cases of thiopurine S-methyltransferase deficient activityAlbain Chansavang, Sadok Maalej, Céline Narjoz, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|April 3, 2023
Screening for dihydropyrimidine dehydrogenase deficiency by measuring uracilemia in chronic kidney disease patients is associated with a high rate of false positivesCéline Narjoz, Zahia Nadour, Aziz Zaanan, et al.
Familial Cancer|August 9, 2011
Microsatellite instability analysis in uterine cavity washings as a screening tool for endometrial cancer in Lynch syndromeJulie Bouquier, Hélène Blons, Céline Narjoz, et al.
Chemical Research in Toxicology|May 19, 2009
Genomic consequences of cytochrome P450 2C9 overexpression in human hepatoma cellsCéline Narjoz, Laetitia Marisa, Sandrine Imbeaud, et al.
Obesity (Silver Spring, Md.)|May 19, 2025
A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesityAurélie Phan, Claire Carette, Céline Narjoz, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 13, 2014
APOL1 polymorphisms and development of CKD in an identical twin donor and recipient pairTomek Kofman, Vincent Audard, Céline Narjoz, et al.
British Journal of Cancer|June 30, 2020
A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiencyNicolas Pallet, Salma Hamdane, Simon Garinet, et al.
Plos One|May 14, 2014
Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistanceCéline Narjoz, Amélie Favre, Justin McMullen, et al.
Pageof 3